Chronic Wound Management: A Complete Guide to Healing Diabetic Ulcers

Diabetic foot ulcers (DFUs) remain one of the most stubborn complications facing clinicians and patients alike. Roughly 15–25 percent of people with diabetes will develop a foot ulcer over their lifetime, and among those who do, nearly 40 percent will see recurrence within 12 months of healing. The numbers paint a sobering picture: standard-of-care protocols get only about a third of ulcers to fully close over 12 to 24 weeks, and infection complicates close to one in five cases during that window. For anyone working in wound care, those gaps demand a hard look at what the evidence says — and where newer antimicrobial approaches like hypochlorous acid (HOCl) fit in.

This guide walks through the pillars of DFU management from a clinical perspective: understanding why these wounds stall, the TIME framework, biofilm’s outsized role, offloading, and where HOCl-based interventions like Spray8 wound care can meaningfully change outcomes. We’ll reference peer-reviewed data throughout so you can take these points directly to practice.

Why Diabetic Ulcers Don’t Heal on Schedule

Before jumping to treatment, it helps to understand the underlying pathophysiology. DFUs are almost never a single-variable problem. Rather, they emerge from overlapping insults that conspire to keep an ulcer locked in a chronic inflammatory state:

• Peripheral neuropathy — Sensory loss means repeated microtrauma goes unnoticed. Motor neuropathy remodels foot architecture, creating abnormal pressure points. Autonomic dysfunction dries the skin, inviting fissures that become entry points for bacteria.
• Peripheral arterial disease (PAD) — Reduced perfusion starves the wound bed of oxygen and nutrients. Even with optimal local care, an ischemic foot simply cannot mount the inflammatory and proliferative responses healing requires without revascularization.
• Hyperglycemia-driven cellular dysfunction — Persistently elevated glucose impairs neutrophil chemotaxis, phagocytosis, and oxidative burst. Collagen synthesis drops. Advanced glycation end-products (AGEs) stiffen the extracellular matrix and cross-link proteins that need to remodel for closure.
• Dysregulated inflammation — Chronic DFUs show elevated matrix metalloproteinases (MMPs) and depressed tissue inhibitors of metalloproteinases (TIMPs). Growth factors get degraded faster than cells can deploy them. The wound essentially digests itself.

All of this is compounded by biofilm — which deserves its own section because it fundamentally changes how we think about infection in a chronic wound.

Biofilm: The Hidden Barrier to Closure

What Makes Biofilm Different from Planktonic Infection

Over 60 percent of chronic wounds harbor biofilm, and in DFUs specifically, polymicrobial biofilm communities — often mixing Staphylococcus aureus, Pseudomonas aeruginosa, and anaerobic species — create a self-protective matrix that resists both immune clearance and topical antibiotics. Bacteria embedded in biofilm can be up to 1,000 times more resistant to antimicrobial agents than their planktonic counterparts. This is one reason why standard antibiotic stewardship alone often fails to move the needle on stalled DFUs.

The clinical implication is straightforward: if you’re not addressing biofilm, you’re not addressing the wound. Mechanical disruption through sharp debridement remains the single most effective anti-biofilm intervention, but debridement alone is insufficient because biofilm recolonizes within 24 to 72 hours. That’s where a topical antimicrobial with anti-biofilm properties becomes critical as a maintenance strategy between debridement sessions.

The Anti-Biofilm Case for HOCl

Hypochlorous acid is a naturally occurring molecule produced by neutrophils during the oxidative burst. It’s been studied extensively as a topical wound antiseptic because it offers broad-spectrum microbicidal activity without the cytotoxicity associated with older agents like povidone-iodine or Dakin’s solution (sodium hypochlorite).

A 2020 in-vitro study by Herruzo and Herruzo (PMID: 31987843) demonstrated that a stabilized HOCl formulation maintained potent antimicrobial activity against both planktonic and biofilm-embedded organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Gram-negative pathogens. The study found that HOCl disrupted biofilm matrix integrity while remaining non-cytotoxic to human keratinocytes and fibroblasts at therapeutic concentrations — a combination that older antiseptics simply cannot match.

The TIME Framework: Structuring DFU Assessment

The International Working Group on the Diabetic Foot (IWGDF) 2023 guidelines (PMID: 37232034) reinforce the TIME model as the backbone of wound bed preparation:

• T — Tissue (non-viable or deficient): Remove necrotic tissue and callus. Sharp surgical debridement is the gold standard. The IWGDF recommends serial debridement every 24–72 hours when necrotic tissue re-accumulates.
• I — Infection or Inflammation: Control bacterial burden and calm chronic inflammation. This is where topical antiseptics with anti-inflammatory properties offer a dual advantage.
• M — Moisture imbalance: Manage exudate. Too dry, and cells desiccate; too wet, and maceration undermines periwound skin. Dressing selection should match exudate level.
• E — Edge of wound (non-advancing): If the wound edge isn’t advancing after addressing T, I, and M, consider advanced therapies — cellular and tissue-based products, negative pressure wound therapy, or angiogenic stimulants.

HOCl solutions address the “I” component directly. A consensus panel of wound care experts led by Armstrong et al. (PMID: 28692424) reviewed the evidence and found strong support for HOCl use specifically in diabetic foot wounds, noting its antimicrobial effectiveness without cytotoxicity and its role as an adjunct to the TIME algorithm and aggressive debridement.

HOCl in Clinical Practice: What the Evidence Shows

Chronic Ulcer Healing Rates

A large prospective study by Herruzo et al. (PMID: 36951216) followed 346 chronic ulcers treated with HOCl formulations. At discharge, 59 percent of ulcers had healed completely. The study found that a sequential protocol — HOCl liquid followed by HOCl gel — produced a synergistic effect: patients were four times more likely to achieve complete healing and one-fifth as likely to develop infection compared to other antiseptic protocols. This liquid-plus-gel approach is particularly relevant for DFUs, where maintaining antimicrobial presence between dressing changes matters.

HOCl vs. Povidone-Iodine in Infected DFUs

A 2024 comparative study published in the Medical Journal Armed Forces India evaluated HOCl (0.02%) against povidone-iodine (10%) in 57 patients with mildly-to-moderately infected DFUs. The HOCl group showed superior antimicrobial activity against Gram-negative organisms, significantly greater reduction in mean ulcer area, and higher percentages of granulation tissue by day 14 and day 30. The authors concluded that HOCl resulted in accelerated wound healing compared to PVP-I — a meaningful finding given how widely povidone-iodine remains in use despite its known cytotoxicity to fibroblasts.

Case Evidence in Diabetic Foot Ulcers

Roos (2022) published case studies of two Type 1 diabetic patients — a 70-year-old female and a 45-year-old male — with DFUs managed using daily gauze dressings saturated with pharmaceutical-grade HOCl. Both ulcers healed with conservative at-home management, avoiding surgical intervention. The authors noted that HOCl’s anti-biofilm properties and inflammation modulation were key factors, and that the simplicity of the gauze-saturation protocol improved patient compliance. For resource-limited settings or patients who struggle with frequent clinic visits, this kind of home-based protocol can be a practical alternative to advanced wound care modalities.

Integrating HOCl Into a Comprehensive DFU Protocol

HOCl is not a standalone cure. It works best as part of a structured, multidisciplinary approach. Here’s how it fits into the broader management algorithm:

1. Vascular Assessment First

Before any topical intervention, confirm adequate perfusion. Ankle-brachial index (ABI), toe pressures, or transcutaneous oxygen pressure (TcPO2) should be obtained. If ABI is below 0.5 or TcPO2 is below 30 mmHg, refer for vascular evaluation. No antimicrobial spray will heal an ischemic wound without revascularization.

2. Sharp Debridement on a Schedule

Debride at initial presentation and reassess every 24–72 hours. The goal is a clean wound bed with bleeding tissue. Apply HOCl solution after debridement to reduce bacterial load and disrupt early biofilm re-formation. The consensus panel recommended ensuring the wound is covered with HOCl solution for at least 15 minutes post-debridement for maximum antimicrobial effect (PMID: 28692424).

3. Offloading Is Non-Negotiable

The IWGDF 2023 offloading guidelines (PMID: 37226568) identify total contact casting (TCC) as the first-line offloading intervention for non-ischemic neuropathic DFUs. Irremovable cast walkers and felted foam are alternatives when TCC isn’t feasible. Without adequate offloading, even the best wound care product will fail — the mechanical shear simply re-injures tissue faster than it can repair.

4. Moisture-Balanced Dressing Selection

Match the dressing to exudate level. For moderately exuding ulcers, HOCl-saturated gauze or a HOCl gel under a foam dressing works well. For dry wounds, a hydrogel base with HOCl spray can rehydrate the wound bed. The key is maintaining a moist environment without maceration.

5. Glycemic Control and Nutrition

HbA1c targets below 7–8 percent, adequate protein intake (1.25–1.5 g/kg/day), and correction of micronutrient deficiencies (zinc, vitamin C, vitamin D) support the cellular machinery that wound healing depends on. These systemic factors are easy to overlook when the focus is on the wound itself, but they matter enormously.

6. Pain Management

DFU-related pain is underreported and undertreated. Neuropathic pain, procedural pain from debridement, and background inflammatory pain all reduce patient compliance with offloading and dressing changes. For patients experiencing significant wound-related pain, an extended analgesic formula can be integrated into the care plan alongside antimicrobial treatment to improve tolerance of debridement and dressing changes.

When to Escalate Beyond Standard Care

Despite optimal management, some ulcers fail to progress. Consider escalation if:

• Less than 20–40 percent area reduction after 4 weeks of standard care
• Signs of deep infection or osteomyelitis (probe-to-bone test, MRI)
• Worsening perfusion despite vascular intervention
• Development of gangrene or necrotizing infection

Advanced options include negative pressure wound therapy (NPWT), cellular and tissue-based products (CTPs), hyperbaric oxygen therapy, and angiogenic growth factor applications. The IWGDF 2023 guidelines provide conditional recommendations for several of these, though the certainty of evidence varies. HOCl can continue as an antimicrobial adjunct alongside these advanced therapies.

Recurrence Prevention: The Other Half of the Battle

Healing a DFU is only step one. Recurrence rates hit 40 percent within a year and climb to 65 percent within five years. Prevention strategies include:

• Custom therapeutic footwear with pressure-relieving insoles
• Regular podiatric follow-up (every 1–3 months)
• Daily foot inspections by the patient or caregiver
• Continued glycemic optimization
• Patient education on early warning signs — warmth, redness, swelling, drainage
• Prophylactic use of HOCl spray on high-risk areas (callus, previous ulcer sites) as part of daily foot hygiene

Frequently Asked Questions

How does HOCl differ from bleach (sodium hypochlorite)?

While both are chlorine-based oxidants, they are chemically distinct. Sodium hypochlorite (NaOCl), commonly known as Dakin’s solution or household bleach, is highly alkaline (pH 11–13) and cytotoxic to healthy tissue at concentrations above 0.025 percent. HOCl is pH-neutral (pH 5.0–6.5), is the same molecule produced naturally by neutrophils, and is non-cytotoxic at therapeutic concentrations (100–500 mg/L). The clinical significance is that HOCl can be used on open wounds without damaging granulation tissue — something bleach cannot claim.

Can HOCl replace antibiotics in infected DFUs?

No. HOCl is an adjunctive topical antimicrobial, not a systemic antibiotic replacement. Deep infections, cellulitis, and osteomyelitis require systemic antibiotic therapy guided by deep tissue cultures. HOCl’s role is to reduce wound surface bioburden, disrupt biofilm, and support the wound bed environment between debridement sessions. It complements — rather than replaces — antibiotic stewardship.

How often should HOCl be applied to a diabetic ulcer?

In the published literature, HOCl has been applied with daily dressing changes (Roos 2022) and in some protocols twice daily. For maintenance between debridement sessions, once-daily application with each dressing change is the most common protocol. The Herruzo et al. study (PMID: 36951216) used HOCl liquid at each wound cleansing followed by HOCl gel under the dressing. Frequency should be adjusted based on exudate level, bioburden, and wound progression.

Is HOCl safe for long-term use on chronic wounds?

Yes. Multiple studies have confirmed the safety profile of pharmaceutical-grade HOCl with extended use. Unlike povidone-iodine (which suppresses fibroblast proliferation) and hydrogen peroxide (which causes oxidative damage to healthy cells), HOCl is selectively toxic to microorganisms while sparing mammalian cells. This selectivity is one reason the expert consensus panel (PMID: 28692424) recommended HOCl as a first-line antiseptic for chronic wound management.

What concentration of HOCl is effective for diabetic ulcers?

Published studies have used concentrations ranging from 0.02% (200 mg/L) to 0.05% (500 mg/L) with demonstrated efficacy. The comparative study against povidone-iodine used 0.02% HOCl and found superior antimicrobial and healing outcomes. The Herruzo et al. study used 100–500 mg/L HOCl liquid. Concentrations below 100 mg/L may lack sufficient microbicidal potency for heavily colonized wounds. Pharmaceutical-grade, stabilized formulations are essential — HOCl degrades rapidly when exposed to light, heat, or organic matter, so product stability directly impacts clinical effectiveness.

Can patients apply HOCl at home, or does it require clinical supervision?

Both models work. The Roos case series demonstrated successful home-based management with HOCl-saturated gauze dressings, with patients or caregivers performing daily changes under remote clinical supervision. This approach reduces clinic visits, lowers costs, and improves quality of life. However, initial assessment, vascular evaluation, and sharp debridement should always be performed by a qualified clinician. HOCl application itself is straightforward enough for home use once the wound bed has been properly prepared.

Key Takeaways

• DFUs are multifactorial — neuropathy, ischemia, hyperglycemia, and biofilm all contribute to stalled healing.
• Biofilm is present in over 60 percent of chronic wounds and must be actively managed, not just treated with antibiotics.
• Sharp debridement remains the cornerstone of wound bed preparation, but biofilm recolonizes within 24–72 hours — making topical anti-biofilm maintenance essential.
• HOCl offers broad-spectrum antimicrobial activity, biofilm disruption, and anti-inflammatory effects without cytotoxicity — a profile that older antiseptics cannot match.
• Clinical evidence (PMIDs: 36951216, 28692424, 31987843) supports HOCl as an effective adjunct in DFU management, with improved healing rates and reduced infection risk.
• HOCl works best within a comprehensive protocol that includes vascular assessment, offloading, moisture-balanced dressings, glycemic control, and pain management.
• For patients managing DFUs at home, HOCl-based products like Spray8 wound care offer a practical, evidence-aligned option that integrates into daily wound hygiene routines.

This article is intended for healthcare professionals and informed patients. It does not replace individualized clinical judgment. Always consult a qualified wound care specialist for DFU management decisions.